Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Shareholders' Equity/Deficit

v3.20.1
Consolidated Statements of Shareholders' Equity/Deficit - USD ($)
Preferred Stock
Common Stock
Additional Paid-in Capital
Retained Earnings
Accumulated Other Comprehensive Income
Total
Noncontrolling Interest
Total
Equity Balance, Starting at Dec. 31, 2017 $ 0 $ 2,281 $ 12,560,619 $ (6,063,977) $ 34,822 $ 6,533,745 $ (187,132) $ 6,346,613
Shares Outstanding, Starting at Dec. 31, 2017 0 22,814,283            
Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments $ 0 $ 45 629,160 0 0 629,205 0 629,205
Stock Issued During Period, Shares, Conversion of Convertible Securities 0 442,597            
Non-controlling distribution $ 0 $ 0 0 0 0 0 (3,534) (3,534)
Net Income (Loss) $ 0 $ 0 0 (409,161) 0 (409,161) (11,118) (420,279)
Shares Outstanding, Ending at Dec. 31, 2018 11 23,139,837            
Equity Balance, Ending at Dec. 31, 2018 $ 0 $ 2,314 13,071,626 (6,438,316) 0 6,635,624 (201,784) 6,433,840
Issuance of Series Q preferred stock $ 0 $ 0 109,985 0 0 109,985 0 109,985
Issuance of Series Q preferred stock, shares 11 0            
Shares canceled, Value $ 0 $ (12) (228,138) 0 0 (228,150) 0 (228,150)
Shares canceled, Shares 0 (117,043)            
Reclassification of unrealized gains on investments in equity securities $ 0 $ 0 0 34,822 (34,822) 0 0 0
Rescind sale of common stock to G Farma, Value $ 0 $ (29) 29 0 0 0 0 0
Rescind sale of common stock to G Farma, Shares 0 (288,890)            
Non-controlling distribution $ 0 $ 0 0 0 0 0 (2,524) (2,524)
Net Income (Loss) $ 0 $ 0 0 (3,436,890) 0 (3,436,890) 18,258 (3,418,632)
Shares Outstanding, Ending at Dec. 31, 2019 11 22,850,947            
Equity Balance, Ending at Dec. 31, 2019 $ 0 $ 2,285 $ 13,071,655 $ (9,875,206) $ 0 $ 3,198,734 $ (186,050) $ 3,012,684